Chart: US-affiliated medical cannabis firms led fundraising on Canadian Securities Exchange in 2018

Just Released! Get realistic market forecasts, state-by-state insights and benchmarks with the new 2024 MJBiz Factbook member program, now with quarterly updates. Make informed decisions.

U.S.-affiliated medical cannabis companies dominated Canadian Securities Exchange (CSE) fundraising in 2018, raising nearly $2 billion through 50 equity-related deals.

As of December 2018, 47% of the 124 cannabis-related companies trading on the CSE were based in the United States or had U.S. assets or interests.

Cannabis-related companies in the life sciences sector – which includes most of the marijuana-related companies listed on the stock exchange – accounted for 76% of all raises by CSE issuers for the year, totaling just under $3 billion through 270 deals.

Cannabis life sciences companies not based or operating in the U.S., including those operating in Canada and Israel, raised $1 billion through 220 deals.

The top eight financing deals – accounting for 35% of 2018 CSE raises – were by U.S.-affiliated cannabis companies.

They include Massachusetts-based Curaleaf Holdings (CSE: CURA) and New York-based Acreage Holdings (CSE: ACRG.U), which led the pack with individual deals valued at more than $300 million each.

The CSE noted that financing through reverse takeovers (RTO) represented 51% of all financing in 2018 – up from 7% in 2017.

Curaleaf, Acreage and other top performers – including Harvest Health & Recreation of Arizona (CSE: HARV) and MedMen Enterprises of California (CSE: MMEN) – are U.S.-based entities that listed on the CSE through RTOs.

Here’s what else you need to know:

  • Of the 123 new CSE listings in 2018, 55 (45%) were cannabis-related companies.
  • The diversified industries fundraising sector – which includes some investment companies that operate in the cannabis space – accounted for 13% of all CSE fundraising, displacing mining to become the second-most-active sector.
  • Financing deals among U.S.-affiliated cannabis companies in the life sciences sector averaged $40 million each, while the average deal size for all other cannabis-related companies in the sector was $4.5 million.

Maggie Cowee can be reached at